Fresenius Medical Care AG (FMS) Form 6-K — Nov 3, 2026
Fresenius Medical Care reported Q3 2026 revenue of €4,937 M, up 1% as reported, but operating income fell 19% to €384 M and net income attributable to shareholders dropped 42% to…
Key figures
- Eps
- €0.61 (Q3 2026); €1.84 (9M 2026)
- Revenue
- €4,937 M (Q3 2026); €14,409 M (9M 2026)
- Guidance
- 2026 capital expenditures anticipated around €0.8 BN to €1.0 BN; TDAPA reimbursement headwind expected to increase in Q4 2026
- Net Income
- €160 M attributable to shareholders (Q3 2026); €496 M (9M 2026)
- Total Debt
- €10,886 M debt and lease liabilities; net debt €9,787 M
- Revenue Yoy
- +1% reported / (1)% constant currency (Q3); (1)% reported / +2% constant currency (9M)
- Total Assets
- €31,449 M
- Cash Position
- €1,099 M as of September 30, 2026
- Headcount
- 106291
- Free cash flow 9m
- €1,229 M
- Net leverage ratio
- 2.6x vs 2.5x at YE 2025
- Fme25 savings target
- €1.2 BN cumulative by end of 2027; €995 M achieved as of September 30, 2026
- Effective tax rate q3
- 25.7% vs 18.7%
- Weighted avg shares q3
- 263.0 M vs 292.1 M prior year
- Operating income q3 2026
- €384 M (-19% YoY)
- Operating margin q3 2026
- 7.8% vs 9.8% prior year
- Same market treatment growth us q3
- -1.1%
AI analysis
Red flags10 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.